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HSAF (1) was isolated from the biocontrol agent Lysobacter enzymogenes (Figure 1).[1-4]
This bacterial metabolite belongs to polycyclic tetramate macrolactams (PTM) that are
emerging as a new class of natural products with distinct structural features.[5, 6] HSAF
exhibits a potent antifungal activity and shows a novel mode of action.[1-4] The HSAF
biosynthetic gene cluster contains only a single-module hybrid polyketide synthase-
nonribosomal peptide synthetase (PKS-NRPS), although the PTM scaffold is apparently
derived from two separate hexaketide chains and an ornithine residue.[1-4] This suggests that
the same PKS module would act not only iteratively, but also separately, in order to link the
two hexaketide chains with the NRPS-activated ornithine to form the characteristic PTM
scaffold. Recently, the Gulder group reported heterologous expression of the ikarugamycin
(4) biosynthetic gene cluster in E. coli,[7] and the Zhang group reported the enzymatic
mechanism for formation of the inner 5-memebered ring and demonstrated the polyketide
origin of the ikarugamycin skeleton.[8] Ikarugamycin is a Streptomyces-derived PTM which
has a 5,6,5-tricyclic system (Figure 1). Both the Gulder and Zhang groups showed that a
three-gene cluster is sufficient for ikarugamycin biosynthesis. Despite the progress, this
iterative polyketide biosynthetic mechanism had not been demonstrated using purified PKS
and NRPS. In addition, HSAF has a 5,5,6-tricyclic system, and its gene cluster contains at
least six genes.[3] Finally, unlike most PTM compounds, HSAF is produced by a Gram-
negative bacterium, L. enzymogenes. Here, we report the heterologous production of HSAF
analogs in Gram-positive Streptomyces hosts, in which the native PKS have been deleted.
We also obtained evidence for the formation of the polyene tetramate intermediate in
Streptomyces when only the single-module hybrid PKS-NRPS gene was expressed. Finally,
we showed the in vitro production of the polyene tetramate using the individually purified
PKS and NRPS. The results provide direct evidence for this iterative polyketide biosynthetic
mechanism that is likely general for the PTM-type hybrid polyketide-peptides.
First, we isolated a cosmid clone, Cos4’-1, from the genomic library of L. enzymogenes C3,
which contains the entire HSAF biosynthetic gene cluster.[2] The gene cluster was then
transferred into vectors for expression in Streptomyces sp. However, the transformants failed
to produce any detectable HSAF or analogs. Subsequently, we made two modifications in
the experiments. One was to replace the putative promoter at the 5′-nontranslated region of
the PKS-NRPS gene with the ermE* promoter.[9-11], generating pSETHSAF3 (Figure S1A).
The other modification was to use an engineered host, strain SR107 derived from
Streptomyces sp. LZ35 through deleting its four native PKS gene clusters.[12, 13] This host is
expected to provide a relatively “clean” background for the heterologous production of
HSAF. We introduced pSETHSAF3 into strain SR107 to generate strain SR107HSAF1 and
analyzed the metabolites in the transformant using HPLC. Strain SR107HSAF1 produced
approximately seven eminent peaks that were absent in the control strain SR107 (Figure 1).
We first focused our attention on the main peak 2 at 18.8 min because it falls in the region
that HSAF and analogs would appear.
Compound 2 was isolated (~1 mg/L titer) as yellow powder. HR-ESI-MS gave a quasi
molecular ion at m/z 495.2837 for [M+H]+ (calculated 495.2853 for C29H38N2O5). The
structure assignments were carried out by the analysis of 1D and 2D NMR data (HSQC,
HMBC and 1H-1H COSY) (Table S1, Figures S14 – S20 in Supporting Information). The
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NMR comparison of 2 with alteramide A (5) indicated that the compounds are structurally
similar,[14] except for the absence of the hydroxyl group at C3 and the Z-geometry for
C10,C11 double bond in 2 (Figure 1 and Table S1). The relative configuration of 2 was
established by proton couplings and NOE correlations. The large coupling constants (~ 15.0
Hz) between olefinic protons (H8/H9, H21/H22, and H23/H24) led to assignment of the E-
configuration for the three double bonds, whereas the Z-configuration of C10,C11 double
bond was deduced from the small coupling constant (11.2 Hz) between H10 and H11. The
relative stereochemistry of the bicycle unit was determined from the NOESY experiment,
which is identical to alteramide A (5).[14] Interestingly, the configuration at C12 in 2 and 5
is opposite to that in 1. Compounds 2 and 5 may result from an alternative stereospecific
cycloaddition that leads to a “wrong” configuration at C12. This consequently may prevent
the formation of the 6-membered ring in 1, as L. enzymogenes PKS-NRPS mutant was not
able to convert 5 to 1.
The rest of the eminent peaks (indicated by asterisks in Figure 1) detected at 380 nm
appeared unstable, and we were not able to obtain the NMR data. To see if any other
isolable HSAF analog was produced in the transformant, we checked the metabolites under
other wavelengths. At 318 nm, two peaks were detected at the HSAF region, one at 18.8 min
(compound 2) and the other at 18.6 min (compound 3) (Figure 1). These two compounds
were not produced by the control strain SR107 (at this wavelength, a main peak at 18.6 min
was also detected in the control, but showed a different UV-Vis spectrum than compound 3).
Compound 3 was then isolated (~0.4 mg/L titer) for structural determination. It appeared as
white powder, with a quasi molecular ion at m/z 497.3021 for [M+H]+ (calculated 497.3015
for C29H40N2O5) as determined by HR-ESI-MS. Comparison of the 1H-NMR spectrum of 3
to that of the previously reported 3-deOH-HSAF readily established the structure of 3 as 3-
deOH-HSAF (Figure 1 and S21-23).[15]
The production of compounds 2 and 3 in a Streptomyces strain supports the notion that the
single-module hybrid PKS-NRPS in pSETHSAF3 is likely sufficient for the assembly of the
PTM scaffold. To further prove this point, we transferred pSETHSAF3 into a second
Streptomyces host that has a completely “clean” background. Strain ZM12 was derived from
S. coelicolor, probably the best-studied model Streptomyces, through deleting all ten native
PKS and NRPS gene clusters present in its genome.[16] HPLC showed that this strain
produced very few metabolites (Figure S2A). However, upon introducing pSETHSAF3,
both compounds 2 and 3 were produced as the main metabolites in strain ZM12, in addition
to a number of minor peaks. Since no other PKS-NRPS is present in strain ZM12, our data
clearly demonstrated that the biosynthesis of HSAF only requires a single-module hybrid
PKS-NRPS. The results also imply that the five domains (KS-AT-DH-KR-ACP) of this PKS
module act two separate times to assemble two separate hexaketide chains.
Compounds 2 and 3 lack the 3-hydroxyl group of HSAF (1), suggesting that the SD gene
(see Figure S1 for the cluster) was not functional in the expression construct pSETHSAF3,
where ermE* promoter was placed in front of the PKS-NRPS gene (Figure S1A). The SD
gene encodes the 3-hydroxylase converting 3-deOH-HSAF (3) to 1.[15] We subsequently
generated a second expression construct pSETHSAF4, where ermE* promoter was placed in
front of the SD gene (Figure S1B). The construct was introduced into Streptomyces sp.
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SR107 to generate the transformant strain SR107HSAF2. However, a careful search of the
metabolites in this strain did not find any HSAF-like compound (Figure S2B). The reason
for this is unclear at this moment; one possibility is that the insertion of the ermE* cassette
in front of SD gene might not lead to the transcription of the PKS-NRPS gene and
downstream tailoring genes because SD gene and the rest genes in the cluster do not appear
to share the same promoter (Figure S1).[15]
To further demonstrate that the single-module hybrid PKSNRPS is able to assemble two
separate polyketide chains and then link them to ornithine, we generated the third
Streptomyces expression construct pSETHSAF5 that contains only the PKS-NRPS gene
under the control of ermE* promoter (Figure S1C). The construct was introduced into
Streptomyces sp. SR107 to generate strain SR107PKS/NRPS. HPLC analysis showed that
the strain produced three new peaks that were absent in the control strain. The peaks showed
absorption λmax around 350-450 nm, suggesting the presence of conjugation systems in all
compounds (Figure S3). The peaks were individually collected and analysed by LC-MS/MS.
Among them, the peak (compound 6) with a retention time of 20.8 min gave a quasi
molecular ion at m/z 475.26 (calculated 475.26 for [M+H]+ for the polyene tetramate 6)
(Figure 2). MS/MS analysis showed fragments of 173.10 and 147.08 that are consistent with
the polyene structure. The same polyene was also observed in the recent heterologous
expression of ikarugamycin PKS/NRPS.[8] Together, the data support that single module
hybrid PKS-NRPS is able to assemble two separate polyketide chains and then link them
with ornithine residue to generate the polyene tetramate (6).
To obtain direct evidence for this iterative single-module PKS, we expressed the PKS in E.
coli and purified the 199.8 kDa protein (Figure S4-6). To test its activity, we converted the
PKS to its holo form by incubating it with CoA and Svp, a promiscuous 4′-
phosphopantetheinyl transferase (PPTase).[17] Due to the huge size of this protein, we
treated the PKS with trypsin after the reaction and followed the mass change of the tryptic
fragment within the ACP domain of the PKS, to which the PPT moiety and biosynthetic
intermediates are covalently linked.[18, 19] Specifically, the trypsin digestion[20] is predicted
to release a 26-residue fragment, VKPEQIDADASLNALGLDSLLAMELR (the active site
serine residue underlined), within the ACP domain.
First, we wanted to confirm that this 26-residue fragment was indeed released from the PKS
that was heterologously expressed in E. coli. Q-TOF-MS showed that the tryptic fragment of
the apo-PKS had m/z 928.1374 for [M+3H]3+ (calculated 928.1604) (Figure 3), and tandem
MS-MS showed that this tryptic fragment had the predicted amino acid sequence (Figure
S7). After the correct tryptic PKS fragment was identified, we analyzed the holo-PKS and
detected a tryptic fragment of m/z 1041.5487 for [M+3H]3+ (calculated 1041.5221) and m/z
781.4270 for [M+4H]4+ (calculated 781.3936) (Figure 3, S8; Table S2). The holo-PKS was
also confirmed using phosphopantetheine ejection assay,[21] which detected m/z 357.2021
(calculated 357.0891) for the predicted PPT-ejected product (Figure S8). The data showed
that the E. coli produced PKS was as expected and the enzyme was active.
Next, we sought for potential biosynthetic intermediates that were covalently attached to the
ACP domain of the PKS. Upon incubating the holo-PKS with malonyl-CoA, acetyl-CoA
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and NADPH, the tryptic fragment released from the PKS showed m/z 1113.4847 for [M
+3H]3+ (calculated 1113.5533) and m/z 835.4001 for [M+4H]4+ (calculated 835.4170)
(Figure 3, S9; Table S2). This mass change of the ACP fragment is coincident with a
hexaketide polyene intermediate attached to the PPT of the PKS (Figure 3). We also varied
reaction conditions and searched for other potential biosynthetic intermediates with a varied
carbon chain. However, the hexaketide polyene was the only one detected. The results are
consistent with that obtained from the heterologous production of HSAF analogs/
intermediate in Streptomyces. Interestingly, the in vitro data suggest that the PKS used
malonyl-CoA as both the starter and the extender in the polyketide chain synthesis because a
carboxylate appeared present in the intermediate (Figure 3 and S9). To verify this, we
generated another PKS expression construct, in which the active site cysteine in the KS
domain of this PKS was mutated to alanine (C176A, protein accession number ABL86391)
(Figure S10). The point-mutated PKS (mPKS) gene was heterologously expressed in E. coli,
and the enzyme was purified and confirmed to contain the C176A mutation by Q-TOF-MS
detection of the tryptic fragment containing the KS active site,
GPSLSIDTAASSSLVAVHLACHSLRR (underlined residue to indicate the C176A
mutation), with m/z 883.16 for [M+3H]3+ (calculated 883.45) (Figure S11). Because all the
domains, except the KS domain, are still active in this PKS, the synthase is expected to
transfer an acyl-CoA (malonyl- or acetyl-CoA) to the ACP but unable to elongate the
polyketide chain. So the acyl group from the starter acyl-CoA will be “stuck” on the ACP
domain. Indeed the ACP domain of the mPKS was 4′-phosphopantetheinylated by Svp, as
evident by the tryptic fragment of m/z 1041.21 for [M+3H]3+ (calculated 1041.52) (Figure
S11). Upon incubating the holo-mPKS with both acetyl-CoA and malonyl-CoA in the
presence of NADPH, we analyzed the acylated ACP fragment. The tryptic fragment showed
m/z 1069.89 for [M+3H]3+ (calculated 1070.19 for malonyl-S-ACP, 1055.52 for acetyl-S-
ACP) and m/z 802.69 for [M+4H]4+ (calculated 802.87 for malonyl-S-ACP, 791.86 for
acetyl-S-ACP) (Figure S12). The results showed that the C176A mutated PKS was active in
transferring the malonyl group from malonyl-CoA, but not the acetyl group from acetyl-
CoA, to the ACP domain (Figure S12). The result demonstrated that the PKS prefers
malonyl-CoA over acetyl-CoA as the starter. It also explains why a carboxylate was
observed in the ACP-bound polyketide intermediate (Figure 3).
Finally, we attempted to reconstitute the activity of HSAF PKSNRPS in vitro using the
individually purified enzymes. The NRPS module (C-A-PCP-TE, 148.6 kDa) was separately
expressed and purified.[3] Prior to reconstituting the activity, the purified NRPS was
converted to the holo form by incubating with CoA and Svp, followed by incubating with L-
ornithine and ATP to form L-ornithine-S-NRPS.[3] Since a thioesterase (TE) domain is
present in this module, we expect the product(s) be released into the reaction
medium.[3, 4, 22] We incubated the polyene-S-PKS with L-ornithine-S-NRPS and used LC-
MS to search for released product from the reconstitution reaction (Figure 4). Total ion
chromatography of selected mass range detected a distinct peak (15.48 min under this LC-
MS condition, see Supporting Information) that was absent in the control reaction. In HR-
ESI-MS analysis, this peak gave m/z 475.2572 that is coincident with the expected [M+H]+
for the polyene tetramate 6 (Figure S13). The result is also in agreement with the in vivo
data where the production of compound 6 was observed in Streptomyces containing the
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PKS-NRPS gene alone (Figure 2). The product of the reconstituted PKS and NRPS did not
contain the carboxylate from the starter malonyl-CoA, suggesting that a decarboxylation
must have taken place after the PKS-linked hexaketide polyene was transferred to the
NRPS. Together, the in vivo heterologous production data (with whole gene cluster and
PKS-NRPS only) and the in vitro enzyme assays (with PKS alone and PKS-NRPS
reconstitution) support that the PKS module acts iteratively and, together the NPRS module,
are sufficient for the synthesis of the framework of PTM.
Based on the results, we proposed a mechanism for the formation of PTM scaffold (Figure
5). First, the five-domain PKS module iteratively catalyzes the formation of a polyene
hexaketide. The geometry of the double bonds is unknown, but most likely to be trans. This
hexaketide is transferred to the four-domain NRPS module, which activates L-orinithine and
catalyzes the first amide bond formation, probably between the delta-amino group of L-
ornithine and thioester carbonyl group of the hexaketide. This leads to an NRPS-bound
polyene-ornithine intermediate. Meantime, the PKS module continues to assemble the
second hexaketide, which is subsequently transferred to the NRPS through forming the
second amide bond, probably between the alpha-amino group of L-ornithine and the second
hexaketide chain. The timing of this transfer is right after the fifth cycle of polyketide chain
elongation, in which the newly formed beta-keto group of the second hexaketide chain has
not been processed by the KR domain and DH domain. All PTM natural products contain
this keto group in the final structure (C25 in HSAF structure, Figure 1).[3, 5, 6, 23] The
determining factor for this timing is not known, but probably related to the redox enzymes
that are proposed to cooperate with the PKS-NRPS in forming the PTM scaffold.[7, 8, 15, 23]
The transfer of the second hexaketide chain leads to a NRPS-bound polyene-ornithine-
polyene intermediate. Finally, the intermediate is released from the NRPS by formation of
the tetramate moiety, which is through the attack of the nucleophilic alpha carbon of the
second hexaketide at the thioester carbonyl carbon of L-ornithine. The presence of the beta-
keto group on the second hexaketide makes the alpha-carbon a good nucleophile, which
promotes the tetramate formation and product release. This perhaps contributes to the timing
of the transfer of this hexaketide to NRPS. In case the beta-keto was fully processed, the
second polyene chain would not undergo tetramate formation, which results in an
“unproductive process”. In vivo, the polyene tetramate 6 is ultimately converted to the PTM
scaffold by tailoring enzymes.[8, 23] Our previous study showed that this NRPS prefers a 12-
carbon chain when forming tetramate acyl-ornithine-acyl products in vitro.[3] Thus, the
specificity of the domain (most likely the C domain) responsible for transferring the
polyketide chain from the PKS to the NRPS is the key determinant for the macrolactam ring
size observed in the characteristic PTM framework.
HSAF is the main antifungal factor that the biocontrol agent Lysobacter enzymogenes uses
to fight against fungal diseases. Lysobacter are ubiquitous in the environment, but largely
remain untapped for bioactive natural products.[23] HSAF has a potent activity against a
broad spectrum of fungi, using a new mode of action. Its chemical structure is distinct from
any existing fungicide or antifungal drug. Most interestingly, its biosynthesis involves an
iterative PKS mechanism. The hybrid PKS-NRPS has a typical modular organization,
including KS-AT-DH-KR-ACP for the PKS module and C-A-PCP-TE for the NRPS
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module. There is no obvious remnants of an inactive enoylreductase (ER°) domain or a
methyltransferase (CMeT) domain, as seen in several iterative fungal PKS-NRPS with the
similar organization, such as PKS for tenellin, lovastain, and compactin.[24-27]. Although
this type of iterative PKS-NRPS is commonly seen in fungi, it is not common in bacteria
until recent years. Furthermore, PTM-type gene clusters have been identified from numerous
bacterial genomes,[5, 6] and the biochemical investigation of this system has only started
recently.[3, 7, 8, 28] Here, our studies of HSAF provide direct evidence for this iterative
biosynthetic mechanism for bacterial polyketide-peptide natural products. The evidence
comes from both the in vivo approach — heterologous production of HSAF analogs and the
polyene tetramate intermediate in the Gram-positive bacterial hosts with a clean
background, and the in vitro approach — expression of the ~200 kDa PKS and the ~150
kDa NRPS separately in E. coli, purification of the giant enzymes, and reconstitution of the
biosynthetic activity. In light of the huge number of uninvestigated PTM-type gene clusters
in databases, our studies present here will facilitate the future exploitation of new PTM
products.
Experimental Section
Details of experimental procedures, construction of expression vectors, production of HSAF
in heterologous hosts, PKS and NRPS gene expression in E. coli, protein purification,
enzyme reactions and activity assay, and spectroscopic data are included in the Supporting
Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Chemical structures of HSAF and other PTM analogs and HPLC analysis of the HSAF
analogs produced in Streptomyces. SR107, metabolites from non-transformed Streptomyces
sp. LZ35 strain SR107, in which four native PKS gene clusters had been deleted;
SR107HSAF, metabolites from strain SR107HSAF1 transformed with the PKS-NRPS
biosynthetic gene cluster under the control of ermE* promoter. The first two HPLC profiles
show the metabolites detected at 380 nm, and the bottom two show the metabolites detected
at 318 nm. The asterisks indicate peaks that were absent in the control.
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Figure 2.
Production of the polyene tetramate (6) in Streptomyces transformed with the PKS-NRPS
only. Top figure, HPLC analysis; bottom figure, MS analysis of 6, with the full ESI-MS at
the left and MS/MS analysis at the right. SR107, metabolites from non-transformed
Streptomyces sp. LZ35 strain SR107; SR107 PKS/NRPS, metabolites from the strain
transformed with only the PKS-NRPS gene under the control of ermE* promoter. The
metabolites were detected at 380 nm. The asterisks indicate peaks that were absent in the
control.
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Figure 3.
Q-TOF MS detection of the 26-residue tryptic PKS fragment that harbors the serine active
site of the ACP domain. Top panel, the tryptic fragment from the PKS produced in E. coli,
with m/z 928.1374 for [M+3H]3+ (calculated 928.1604); mid panel, the tryptic fragment
from the 4′-phosphopantetheinylated PKS, with m/z 1041.5487 for [M+3H]3+ (calculated
1041.5221); bottom panel, the tryptic fragment from acylated PKS, with m/z 1113.4847 for
[M+3H]3+ (calculated 1113.5533), showing the hexaketide polyene synthesized by the
single-module PKS.
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Figure 4.
Analysis of the in vitro reconstituted PKS-NRPS. Total ion chromatography of the mass
(475.2597) for compound 6 is shown for the control reaction (top panel) and the PKS-NRPS
reaction (bottom). The peak at 15.48 min in the PKS-NRPS reaction gave m/z 475.2572 in
HR-ESI-MS.
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Figure 5.
A proposed biosynthetic mechanism for the iterative bacterial PKS-NRPS in the assembly of
the scaffold of HSAF and analogs.
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1. Strains, Vectors, Chemicals and Molecular Biology Agents  
Escherichia coli DH5α and EPI300 (Epicenter Biotechnologies, Madison, WI) were used as the hosts for 
general plasmid DNA propagation. E. coli SG13009 (pREP4) were used for protein expression. E. coli 
BW25113/pKD46 was used for Red recombination. E. coli ET12567/pUZ8002 was used as the conjugal 
strain. Streptomyces sp. LZ35 was isolated from the intertidal soil collected at Jimei, Xiamen, China.[12] 
Strain SR107 was derived from Streptomyces sp. LZ35 by deletion of four PKS gene clusters.[13] Strain 
ZM12 was derived from S. coelicolor by deletion of all ten native PKS and NRPS gene clusters present in 
its genome.[16] Strains SR107 and ZM12 were used as the hosts for the heterologous production of HSAF. 
Vector pANT841 was used for general cloning, vector pQE60 was used for protein expression in E. coli 
SG13009 (pREP4), and vector pSET152 was used for integration of the HSAF gene cluster into 
Streptomyces hosts. Chemicals were purchased from Sigma or Fisher Scientific. PCR primers were 
synthesized by Integrated DNA Technologies (IDT, Coralville, IA). Kits for plasmid preparation and 
DNA extraction were from Qiagen (Valencia, CA). Standard molecular biology methods were used for all 
other DNA manipulations. 
2. Construction of HSAF expression vectors and heterologous production in Streptomyces 
To subclone the HSAF gene cluster into the integrative vector pSET152, two restriction sites, AclI and 
BamHI, were introduced into the vector by insertion of two DNA fragments (Figure S1). The two 
fragments (1.4 and 1.7 kb) were amplified from the cosmid clone, Cos4'-1, which contains the entire 
HSAF gene cluster isolated from Lysobacter enzymogenes C3.[2] The following two pairs of primers were 
used for the PCR:  
HSAF-LF, Left-BglII-Forward: 5'-GAA GAT CTC GGG AAA CTC CGA GGC AGA AAT-3'  
HSAF-LR, Left-EcoRI-Reverse: 5'-AGG AAT TCC GGT GAT GCA AGG GCT GTC GA-3'  
HSAF-RF, Right-EcoRI-Forward: 5'-AGG AAT TCA ACA CCT GGA GTT CTT CAG CAT CA-3' 
HSAF-RR, Right-BglII-Reverese: 5'-GAA GAT CTA AAT CAG CGC CGG TGG CGT TG-3'  
  
Figure S1. Strategy for constructing the HSAF expression vectors for the production of HSAF analogs in 
Streptomyces hosts. A, construct pSETHSAF3 that resulted in the recombinant Streptomyces strains 
SR107HSAF1 and ZM12HSAF1; B, construct pSETHSAF4 that resulted in the recombinant 
Streptomyces strain SR107HSAF2; C, construct pSETHSAF5 resulting in the recombinant Streptomyces 
strain SR107PKS/NRPS.  
 
The resulting PCR products were digested with BglII and EcoRI, respectively, and ligated to the BamHI-
digested pSET152 to create pSETHSAF1. Then, a 17.2 kb fragment harboring the bulk of the HSAF gene 
cluster was cut off from Cos4'-1 by digestion with AclI and BamHI and inserted into the same sites of 
pSETHSAF1 to yield pSETHSAF2 (Figure S1). 
The λ Red mediated recombination in E. coli BW25113/pKD46 [11] was used to replace the native 
promoter of the PKS-NRPS gene or of the SD gene with Streptomyces ermE* promoter.[9, 10] About 100 
ng of pSETHSAF2 was transformed into E. coli BW25113/pKD46 by electroporation at 2500 V, 25 μF, 
and 200 Ohms. Clones were selected on solid LB agar with 100 μg/ml ampicillin and 30 μg/ml apramycin. 
The transformants were cultured in LB medium at 30 ℃ and induced by addition of 10 mM L-arabinose 
for the expression of the red genes. Two fragments including the chloramphenicol-resistance cassette (Cm) 
and the ermE* promoter were amplified from pUC19-Cm-PermER* (unpublished data) using the 
following two pairs of primers, respectively:  
ER2HSAFF: 5'-gaa cca gtt tgt tcc aga tca cgg ccg gaa cgc gtt ccg ACA GCT TAT CAT CGA ATT TC-3'  
ER2HSAFR: 5'-gcg gca gcc gat gcc gat gat ggc gat gcg gtc ctc cat ATG TCC GCC TCC TTT GGT CG-3'   
CmER2SDF: 5'-cgc cgc ggc cta gcc gcg aat att cgc cgg cat tat ctg ACA GCT TAT CAT CGA ATT TC-3' 
CmER2SDR: 5'-agc acg cgt ttc caa agt gtg ctc tga taa tcc gtt cat ATG TCC GCC TCC TTT GGT CG-3' 
 
(note: the bases in lower case are the sequence for Red recombination, and the bases in upper case are for 
amplification of the target genes) 
Each of the fragments (~ 200 ng) was electroporated into E. coli BW25113/pKD46/pSETHSAF2 to 
generate pSETHSAF3 and pSETHSAF4, respectively. Transformants were selected for resistance to 
chloramphenicol at 25 μg/ml. In addition, the 10 kb SpeI /NheI fragment from pSETHSAF3 was inserted 
into the XbaI site of pSET152 to create pSETHSAF5, which only contained the PKS/NRPS gene with the 
ermE* promoter. The constructs pSETHSAF3 - 5 were individually transformed into E. coli 
ET12567/pUZ8002, which were used to mate with Streptomyces sp. SR107 and ZM12. This intergeneric 
conjugation resulted in the transfer of three different HSAF expression constructs into Streptomyces hosts, 
construct pSETHSAF3 leading to the recombinant strains SR107HSAF1 and ZM12HSAF1, construct 
pSETHSAF4 to strain SR107HSAF2, and construct pSETHSAF5 to strain SR107PKS/NRPS. 
3. Production and analysis of the metabolites in Streptomyces strains 
For production of secondary metabolites, all Streptomyces strains were inoculated on petri dishes 
containing the Fermentation Medium (soluble starch 25 g, soybean 15 g, yeast extract 2 g, agar 20 g, pH 
7.2, 40 ml) and cultivated at 28 °C for 11 days. The whole solid cultures were diced and extracted with 
AcOEt/MeOH/AcOH (80 : 15 : 5, v/v/v) at room temperature, and the crude solution was concentrated 
under reduced pressure. The dried extract was dissolved in 2 ml methanol, and a 20 μl aliquot of each 
extracts was analyzed by HPLC (Agilent 1200, ZORBAX Eclipse XDB-C18, 4.6×250 mm, 5 μ). For 
SR107HSAF1-2 and ZM12HSAF1, chromatographic conditions were as follows: solvents-A, water-0.04% 
trifluoroacetic acid (TFA); solvent-B, acetonitrile-0.04% TFA; solvent gradient from 20% B to 35% B in 
the first 3 min, increased to 45% at 10 min, to 90% B at 17 min, followed by 3 min with 90% B, to 100% 
B at 22 min, followed by 4 min with 100% B; flow rate 1 ml/min and UV detection at 380 nm or 318 nm 
(Figure 1 and S2). For SR107PKS/NRPS, chromatographic conditions were as follows: solvents-A, 
water-0.1% formic acid (FA); solvent-B, acetonitrile-0.1% FA; solvent gradient from 20% B to 55% B in 
the first 5 min, increased to 70% at 8 min, followed by 8 min with 70% B, to 100% B at 17 min, followed 
by 3 min with 100% B, to 20% B at 21 min, followed by 4 min with 20% B; flow rate 1 ml/min and UV 
detection at 380 nm (Figure 2) 
 Figure S2. HPLC analysis of metabolites from Streptomyces strain ZM12HSAF1 (A) and strain 
SR107HSAF2 (B). Strain ZM12HSAF1 was generated by introducing the construct pSETHSAF3 (ermE* 
promoter placed before the PKS-NRPS gene of the cluster) into Streptomyces coelicolor ZM12, in which 
all the ten native PKS and NRPS gene clusters have been deleted.[16] Strain SR107HSAF2 was generated 
by introducing the construct pSETHSAF4 (ermE* promoter placed before the SD gene of the cluster) into 
Streptomyces sp. SR107, in which four PKS genes have been deleted.[12, 13] The metabolites were detected 
at 318 nm. The chemical structure of compounds 2 and 3 were determined and shown in Figure 1, and the 
asterisks indicate peaks that were absent in the control.  
 
4. Isolation and structure determination of compounds 2 and 3 
SR107HSAF culture (10 liters) was allowed to grow on the Fermentation Medium at 28 °C for 11 days. 
The whole solid cultures were diced and extracted three times with AcOEt/MeOH/AcOH (80 : 15 : 5, 
v/v/v) at room temperature, and the crude extract solution was concentrated under reduced pressure, and 
the concentrated extract was sequentially solvent partitioned into petroleum ether-soluble extract and 
MeOH-soluble extract. The MeOH extract was loaded to a Sephadex LH-20 column for separation. The 
column was eluted with MeOH to obtain six fractions, Fr.1 - 6. Fr.3 was subjected to medium-pressure 
liquid chromatography (MPLC; 80 g RP-18 silica gel; acetonitrile/H2O 30%, 50%, 70%, 80%, and 100%, 
200 ml each) to afford five subfractions, Fr.3a – 3e. Fr.3c (60 mg) was subjected to preparative HPLC 
(Agilent 1200, ZORBAX Eclipse XDB-C18, 9.4×250 mm, 5 μ), using an isocratic solvent of 55% 
acetonitrile-0.04% TFA, at flow rate of 4 ml/min, detected at UV 360 nm. This afforded compound 2 (10 
mg) and compound 3 (4 mg). To determine the structures of the compounds, 1D- and 2D-NMR were 
performed on a Bruker DRX-600 spectrometer. MS was carried out on an LTQ-Orbitrap-XL mass 
spectrometer (Thermo Scientific). 
 
Table S1. The 1H- and 13C-NMR spectroscopic data for compound 2, at 600 MHz and 150 MHz, in 
DMSO-d6, respectively; J in ppm 
Position 1H 13C Position 1H 13C 
1  195.6s 17 1.36 (m) 47.0d 
2 3.84 (t, J = 5.4) 61.0d 18 2.10 (q, J = 9.7) 55.4d 
3 1.84 (m) 25.7t 19 1.83 (m) 55.5d 
4 1.38 (m) 1.17 (m) 20.6t 20 3.78 (t, J = 9.7) 74.2d 
5 3.28 (m)  2.45 (t, J = 9.1) 38.1t 21 6.11 (m) 147.1d 
6 7.97 (t, J = 5.4)  22 6.03 (dd, J = 15.0, 11.1) 128.3d 
7  164.8s 23 7.29 (dd, J = 15.4, 11.1) 142.3d 
8 5.90 (d, J = 14.8) 125.6d* 24 6.83 (d, J = 15.4) 121.4d 
9 6.95 (t, J = 13.3) 132.9d 25  175.2s 
10 6.13 (m) 125.5d* 26  100.8s 
11 5.80 (t, J = 11.2) 139.0d 27  171.9s 
12 3.07 (m) 44.6d 28 8.73 (s)  
13 1.55 (m) 40.6t 29 1.09 (d, J = 6.3) 18.6q 
14 2.63 (m) 41.8d 30 1.59 (m) 1.07 (m) 26.0t 
15 2.05 (m) 0.88 (m) 40.1t 31 0.86 (t, J = 7.2) 12.5q 
16 1.39 (m) 53.7d    
* exchangeable. 
 
5. LC-MS-MS analysis of the metabolites in strain SR107PKS/NRPS  
Strain SR107PKS/NRPS containing the construct pSETHSAF5 (PKS-NRPS alone under the control of 
ermE* promoter) generated three new peaks as shown in Figure 2. To identify the metabolites, the peaks 
were individually collected from HPLC, and each of the peaks was further analyzed by UV-Vis 
spectrometry (Figure S3) and HPLC-HRMS using a Prominence Modular HPLC (Shimadzu Corporation, 
YMC-Pack Pro C18, 5 μm, 4.6 × 250 mm) coupled to a LTQ Velos Pro HRMS instrument (Thermo 
Scientific). For peak1, chromatographic condition was 60% acetonitrile/H2O (containing 0.2% FA) for 10 
min; for peaks 2 and 3, chromatographic condition was 85% acetonitrile/H2O (containing 0.2% FA) for 
10 min. 
 Figure S3. UV-Vis spectra of the three peaks observed in HPLC of the metabolites from Streptomyces 
strain SR107PKS/NRPS that was transformed with PKS-NRPS alone. A, peak at 11.7 min; B, peak at 
16.3 min; C, peak at 20.8 min (polyene tetramate 6). 
 
6. HSAF polyketide synthase (PKS) expression in E. coli  
The procedure for constructing the entire PKS gene (5526 bp) for expression in E. coli is illustrated in 
Figure S4. Two of the three pieces that make up the complete PKS gene were amplified by PCR using 
Cos4'-1 as the template. The following two pairs of primers were used for the PCR:  
P1, KS-NcoI-Forward: 5'-GAG ACC ATG GAG GAC CGC ATC GCC A-3' 
P2, KS-EcoRI-Reverse: 5'- CAT CAT CGT GCC GGT GGC GGT G-3' 
P3, ACP-KpnI-Forward: 5'- ACC GCG GCG ATG CGG TCG AAC-3' 
P4, ACP-BamHI-Reverse: 5'- GGG AAG GAT CCC AGC GCG TTC TGG T-3' 
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Figure S4. Strategy for constructing the PKS expression vector for the production of the enzyme in E. 
coli. 
 
The KS-fragment (218 bp) amplified by primers P1/P2 was digested with NcoI and EcoRI; the ACP-
fragment (1411 bp) amplified by primers P3/P4 was digested with KpnI and BamHI (Figure S4). Both 
fragments were cloned into pANT841 at the respective restriction sites. The middle fragment of the PKS 
was obtained by digesting Cos4'-1 with EcoRI, followed by digestion of the resulted fragment (5941 bp) 
with KpnI. The larger EcoRI/KpnI fragment (3897 bp) was cloned into pANT841 at the same sites. The 
three pieces were ligated together to generate pANT841-PKS (8303 bp). The construct was sequenced to 
verify the identity of the PKS gene. Finally, the PKS gene was released from pANT841-PKS as an 
NcoI/BamHI fragment and cloned into the expression vector pQE60 (Figure S4 and S5). 
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Figure S5. Gel electrophoresis to check the constructs for PKS expression in E. coli. A, PCR 
amplification of the KS-fragment and the ACP-fragment; B, the EcoRI/KpnI fragment (3897 bp) of the 
PKS obtained by enzyme digestion of the cosmid clone, Cos4'-1; C, NcoI/BamHI digestion of pQE60-
PKS to confirm the final construct for expression.  
 
To express the PKS, pQE60-PKS was introduced into E. coli SG13009. Individual single colonies were 
inoculated in 3 ml of liquid LB medium containing ampicillin (50 µg/ml), and the culture was incubated 
in a shaker (250 rpm) at 37 °C overnight. The overnight culture was added to 50 ml fresh LB medium and 
continued in a shaker (250 rpm) at 37 °C until the cell density (OD600nm) reached 0.6. To induce the 
expression of the PKS, IPTG (final concentration 0.3 mM) was added to the culture, and the cells were 
allowed to grow (250 rpm) at the room temperature for another 12 hours. To extract proteins, the cells 
were harvested and resuspended in 2 ml of PBS buffer (500 mM NaCl, 50 mM Na2HPO4, 50 mM 
NaH2PO4, pH 7.8). The cell suspension was sonicated on ice, and the soluble fraction of protein extracts 
was loaded onto a Ni-NTA column, which was previously calibrated with the PBS buffer containing 10 
mM imidazole. The column was washed three times with the buffer containing 20 mM imidazole, and the 
C-His6-tagged PKS protein (199.8 kDa) was purified by using an imidazole step-gradient as described by 
the manufacturer’s protocol. The purity of the protein was analyzed by SDS-PAGE (Figure S6), and the 
fractions containing the purified PKS were pooled, concentrated, and dialyzed against a buffer containing 
50 mM NaCl, 50 mM Na2HPO4, 50 mM NaH2PO4, pH 7.8, and 15% glycerol. Finally, the protein 
preparation was frozen in liquid nitrogen and stored at -80 °C until use. 
199.8 kDa
 
Figure S6. SDS-PAGE of the HSAF PKS expressed in E. coli. M, markers; BI, total proteins before 
IPTG induction; SN, total soluble proteins after sonication; P, total precipitated proteins after sonication; 
FT, flow-through fraction of the Ni-NTA column; WB1-3, wash-off fractions of the Ni-NTA column; 
EB1-15, imidazole-eluted fractions of the Ni-NTA column. The purified PKS is indicated with an arrow. 
 
7. In vitro assay for the activity of the PKS module 
The first step was to convert the purified PKS to its holo form, through 4'-phospho-pantetheinylation at 
the active site serine residue of its ACP domain. This was carried by Svp,[17] a promiscuous 4'-
phosphopantetheinyl transferase (PPTase). The reaction contained the PKS protein (25 µM), CoA (2 mM) 
and Svp (10 µM), in a 45 µl solution of Tris-HCl (100 mM, pH 8.0), MgCl2 (10 mM), and TCEP (0.5 
mM). After incubation at 37 °C for 2 h, the reaction was stopped by boiling for 10 min. Due to the huge 
size (199.8 kDa) of the PKS protein, a trypsin digestion procedure was employed prior to the ESI-Q-TOF 
analysis of the mass of the PKS. The protein was loaded to a SDS-PAGE (7.5%), and the PKS band was 
excised from the gel and subjected to trypsin digestion.[20] Briefly, gel pieces were digested by trypsin 
(no.V5111, Promega, Madison, WI) and digested peptides were extracted in 5% formic acid / 50% 
acetonitrile and separated using C18 reversed phase LC column (75 micron × 15 cm, BEH 130 , 1.7 
micron Waters, Milford, MA). A Q-TOF Ultima tandem mass spectrometer couple with a Nanoaquity 
HPLC system (Waters) with electrospray ionization was used to analyze the eluting peptides. The system 
was user controlled employing MassLynx software (v 4.1, Waters) in data-dependent acquisition mode 
with the following parameters: 0.9-sec survey scan (380–1900 Da) followed by up to three 1.4-sec 
MS/MS acquisitions (60–1900 Da). The instrument was operated at a mass resolution of 8000. The 
instrument was calibrated using the fragment ion masses of doubly protonated Glu-fibrinopeptide. The 
peak lists of MS/MS data were generated using Distiller (Matrix Science, London, UK) using charge state 
recognition and de-isotoping with the other default parameters for Q-TOF data. Data base searches of the 
acquired MS/MS spectra were performed using Mascot (Matrix Science, v2.2.0, London, UK). The NCBI 
database (20100701) was used in the searches. Search parameters used were: no restrictions on protein 
molecular weight or pI, enzymatic specificity was set to trypsin with up to 3 missed cleavage sites, 
carbamidomethylation of C was selected as a fixed modification, and methionine oxidaztion was selected 
as a variable modification. Mass accuracy settings were 0.15 daltons for peptide mass and 0.12 daltons for 
fragment ion masses. The apo-PKS, holo-PKS, and the various forms of acylated PKS were analyzed by 
the MS method, which had been successfully used in other studies.[18, 19]    
The trypsin digestion of this apo-PKS is expected to release a 26-residue fragment, VKPEQ IDADA 
SLNAL GLDSL LAMELR, which contains the active site serine residue (underlined) of the ACP domain 
of the PKS (Table S2, shown the mass of a number of selected ions, both the predicted and the observed). 
Q-TOF MS data showed that the tryptic fragment from the apo-PKS isolated from E. coli had m/z 
928.1374 for [M+3H]3+ (calculated 928.1604) (Figure 3). This fragment was subject to tandem MS-MS 
analysis (Figure S7). The result showed that this tryptic fragment had the expected amino acid sequence, 
confirming that the 199.8 kDa protein purified from E. coli was HSAF PKS. 
 
 
 
 
 
  
Table S2. The predicted mass and observed mass of the tryptic PKS fragment containing the ACP 
domain. 
 
 
 
Figure S7. Tandem MS-MS data for the tryptic PKS fragment that harbors the serine active site of the 
ACP domain, VKPEQ IDADA SLNAL GLDSL LAMELR. 
 
Substrate Predicted 
product 
Predicted Mass (Da) Observed Mass (Da) Error (Da) 
M+3H M+4H M+3H M+4H M+1H 
- apo-PKS 928.1604 696.3722 928.1347 NA 0.0613 
CoA holo-PKS 1041.5221 781.3936 1041.5487 781.4270 0.0798 
Mal-CoA PKS-polyene 1113.5533 835.4170 1113.4847 835.4001 0.2058 
Upon 4'-phosphopantetheinylation, the tryptic fragment from the holo-PKS is expected to have a 340.1 
mass increase. Q-TOF MS data showed m/z 1041.5487 for [M+3H]3+ (calculated 1041.5221) (Figure 3) 
and m/z 781.4270 for [M+4H]4+ (calculated 781.3936) (Figure S8, top panel). In addition, the 4'-
phosphopantetheinylation of the PKS was examined using PPT ejection assay.[21] The expected 
compound was detected from the holo-PKS (Figure S8, bottom panel).  The results demonstrated that the 
apo-form of the PKS expressed in E. coli had been converted into its holo-form in vitro.  
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Figure S8. Top panel, Q-TOF MS detection of the 26-residue tryptic fragment from the 4'-
phosphopantetheinylated PKS, with m/z 781.4270 for [M+4H]4+ (calculated 781.3936); bottom panel, MS 
detection of the compound resulted from a PPT ejection, with m/z 357.2021 for [M]- (calculated 
357.0891).  
 To test the activity of the PKS, the reaction mixture (45 µl) containing the holo-PKS was added with 
malonyl-CoA (10 mM), NADPH (10 mM) and acetyl-CoA (2 mM), and the final volume was brought to 
50 µl. The reactions were incubated at 37 °C for 20 h. A reaction containing boiled PKS protein served as 
the control. The reactions were stopped by boiling for 10 min, and a 10 µl aliquot of the reaction mixtures 
was loaded on SDS-PAGE (7.5%), and the PKS band was cut out for trypsin digestion. The 26-residue 
tryptic fragment was then analyzed by MS. Since the acyl chain synthesized by the PKS could have 
various chain lengths and oxidation levels, the samples were subject thorough search for various potential 
acylated products. However, hexakitide polyene appeared to be the only one that was detectable under the 
experimental conditions (Figure 3 and S9). 
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Figure S9. Q-TOF MS detection of the 26-residue tryptic fragment from acylated PKS, with m/z 
835.4001 for [M+4H]4+ (calculated 835.4170), showing the hexaketide polyene synthesized by the single-
module PKS (also see Figure 3).  
 
8. Expression of PKS with a point-mutated KS domain in E. coli and activity assay of the synthase 
The in vitro data obtained from the purified PKS suggest that the synthase may use malonyl-CoA as both 
the starter and the extender in the polyketide chain synthesis because a carboxylate appeared present in 
the intermediate (Figure 3). To probe the starter specificity, we generated another PKS expression 
construct, in which the active site cysteine in the KS domain of this PKS was mutated to alanine (C176A, 
with the protein accession number ABL86391). Primer extension PCR was performed to generate a 2151-
bp fragment of PKS gene with C176A mutation. The following two pairs of primers were used to amplify 
a 359-bp fragment and a 1832-bp fragment (Figure S10): 
KS(C/A) up-fw: 5'-CGC GGC GGC TAC ATC GAC GGC TTC GAC G-3' 
KS(C/A) up-rv: 5'-GGC GAC CAG GGA GGA ACT AGC GGC GGT GTC GAT CGA CAG GCT-3' 
KS(C/A) down-fw: 5'-AGC CTG TCG ATC GAC ACC GCC GCT AGT TCC TCC CTG GTC GCC-3' 
KS(C/A) down-rv: 5'-GTA GAG CTC GTG GCC GGC GGC GAT GCC-3' 
After purification of the PCR fragments, an overlapping PCR was carried out using these 2 fragments as 
template. The resulted 2151-bp fragment was digested with EcoRI and SacI, and cloned into previously 
constructed pANT841-PKS (Figure S4) at the same sites. The mutated PKS gene (mPKS) was released 
from pANT841 as a BamHI/NcoI fragment and cloned into expression vector pQE60 (Figure S10). The 
subsequent expression and purification are the same as for the wild type PKS. 
A B C D 
     
Figure S10. Construction of the expression vector for the KS active-site mutated PKS (mPKS) and 
expression of the enzyme in E. coli. A, PCR amplification of the KS upstream fragment (359-bp) and 
downstream fragment (1832-bp). These two fragments were used as templates in overlapping PCR. The 
marker is the 1 kb ladder from Fermentas. B, Overlapping PCR. Lane 1 is the overlapping PCR fragment 
(2151-bp), which harbors the C/A mutation site; lane 2 is the pANT841-PKS (original) vector digested by 
EcoRI and SacI. Marker is the high range ladder No.393 from Fermentas. C, analysis of the expression 
construct pQE60-mPKS. Lane 1 is NcoI and BamHI double digested pQE60-mPKS, resulted in 2 bands 
of the expected lengths (5562-bp and 3431-bp). D, SDS-PAGE of the mPKS expressed in E. coli. M, 
markers; SN, total soluble proteins after sonication; FT, flow-through fraction of the Ni-NTA column; 
EB1-5, imidazole-eluted fractions of the Ni-NTA column. The purified PKS is indicated with an arrow. 
  
To assay the activity, mPKS (25 µM) was first converted into its holo form, by incubating with CoA (2 
mM) and Svp (10 µM) in a 50 µl reaction containing Tris-HCl (100 mM, pH 8.0), MgCl2 (10 mM), and 
TCEP (0.5 mM). After incubation at 37 °C for 2 h, the reaction mixture was added with 10 mM malonyl-
CoA, 2 mM acetyl-CoA, and 10 mM NADPH. A reaction containing the wild type PKS served as the 
control. After continual incubation at 37°C for 20 h, the reactions were stopped by boiling. A 10 µl 
aliquot of the reaction mixtures was loaded on SDS-PAGE for analysis. The mPKS band was cut from the 
gel and subject to trypsin digestion and Q-TOF MS analysis as described above. 
A B C 
   
Figure S11. Q-TOF MS data for the tryptic fragment of mPKS. A, MS data confirming the C176A 
mutation in the tryptic fragment from the KS domain, GPSLSIDTAASSSLVAVHLACHSLRR 
(underlined residue to indicate the C176A mutation), with m/z 883.16 for [M+3H]3+ (calculated 883.45).  
B and C, MS data to show that the KS point-mutated PKS is active in 4'-phosphopantetheinylation by Svp, 
using CoA as substrate; the 26-residue tryptic fragment from the 4'-phosphopantetheinylated ACP domain 
gave m/z 1041.21 for [M+3H]3+ (calculated mass: 1041.52). 
 
Q-TOF MS confirmed the C176A mutation in the KS domain of mPKS and the 4'-
phosphopantetheinylation of the ACP domain (Figure 11S). When holo-mPKS was incubated with both 
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acetyl-CoA and malonyl-CoA in the presence of NADPH, we detected the tryptic fragment with m/z 
1069.89 for [M+3H]3+ (calculated 1070.19 for malonyl-S-ACP, 1055.52 for acetyl-S-ACP) and m/z 
802.69 for [M+4H]4+ (calculated 802.87 for malonyl-S-ACP, 791.86 for acetyl-S-ACP) (Figure S12). The 
results showed that the PKS prefers malonyl-CoA over acetyl-CoA as the starter. 
A B C 
   
Figure S12. Q-TOF MS data for the tryptic fragment of holo mPKS, after incubating with malonyl-CoA, 
acetyl-CoA and NADPH. A, m/z 1069.89 for [M+3H]3+ (calculated 1070.19 for tryptic malonyl-S-ACP, 
1055.52 for tryptic acetyl-S-ACP); B, m/z 802.69 for [M+4H]4+ (calculated 802.87 for tryptic malonyl-S-
ACP, 791.86 for tryptic acetyl-S-ACP); C, the 26-residue tryptic fragment from malonyl-S-ACP. 
 
9. In vitro reconstitution of the PKS module and the NRPS module 
The PKS module was activated to its holo-form and incubated with proper substrates as described in the 
reactions above. The expression and purification of the NRPS module had been described previously.[3] 
The purified NRPS module was also converted to its holo form by incubating with CoA (0.83 mM) with 
Svp (5.6 µM) in a 60 µl reaction containing Tris-HCl (100 mM, pH 8.0), MgCl2 (10 mM), and TCEP (0.5 
mM). The reactions were incubated at 37 °C for 2 h. The NRPS reaction mixture and the PKS reaction 
mixture were then combined into a tube, which had a 40 µl solution containing L-Orn (1.5 mM), ATP (3 
mM), Tris-HCl (100 mM, pH 8.0), MgCl2 (10 mM), NaCl (50 mM), EDTA (0.1 mM), and TCEP (0.5 
mM). For control, the reaction contained all the components of the reconstitution reaction except that 
NRPS was replaced with the total proteins of the E. coli host strain that was transformed only with the 
blank expression vector pQE60. After continual incubation for 5 h at 37 °C, the reactions were stopped by 
adding 150 µl of 0.2 mM TCA in methanol and were frozen at -20 °C for 30 min. The mixtures were 
centrifuged at 13,200 rpm for 20 min in a desktop Eppendorf centrifuge, and the supernatants were 
transferred to new tubes. The solutions were dried in a Speed-Vac, and the residues in the tubes were re-
dissolved in 150 µl methanol. The methanol extracts were centrifuged, and supernatants were transferred 
to new tubes and dried again. Finally, the residues in the tubes were re-dissolved in 300 µl 50% methanol 
and analyzed by LC-MS. The sample (50 µl) was loaded to a Waters BEH column (C18 1.7 µm, 1.0 × 
100 mm), and eluted with the following solvent program: Solvent A was H2O containing 0.1% formic 
acid; Solvent B was acetonitrile containing 0.1% formic acid. The flow rate was 50 µl/min with a binary 
gradient system (0-15 min, 5%-45% B gradient; 15-35 min, 45% B to 90% B gradient; 35-46 min, 90% B 
to 100% B gradient; 46-55 min, 100% B; 55-56 min, 100% B to 5% B gradient; 56-66 min, 5% B). The 
mass spectrometer was Mass Spec Waters Snapt G2-S Q-TOF, operated in positive ion high resolution 
mode with lock mass, mass range 100-1200 amu, 1sec scans. 
The LC-MS was set to scan for various masses of potential products that could be synthesized by the 
reconstituted PKS-NRPS and then released into the medium by the thioesterase (TE) domain in the NRPS 
module.[3, 4, 22, 23] One eminent peak at 15.48 min was detected in the reconstituted reaction, but no in the 
control reaction, when the scan was at m/z 475.2597 (Figure 4). This peak was subject to HR-ESI-MS 
analysis and gave m/z 475.2572  (Figure  S13). This mass is coincident with the expected [M+H]+ for the 
polyene tetramate 6.  
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Figure S13. Q-TOF MS analysis of the polyene tetramate (6) produced in the in vitro reconstituted PKS 
and NRPS reaction. The m/z 475.2572 is consistent with [M+H]+ of compound 6 (calculated 475.2597).   
Below are NMR data for Compounds 2 and 3 whose structures are shown in Figure 1. 
 
 
Figure S14. 1H NMR spectrum of 2 in DMSO-d6. 
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 Figure S15. 13C NMR spectrum of 2 in DMSO-d6. 
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 Figure S16. The HSQC spectrum of 2 in DMSO-d6. 
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 Figure S17. The HMBC spectrum of 2 in DMSO-d6. 
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 Figure S18. The 1H - 1H COSY spectrum of 2 in DMSO-d6. 
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 Figure S19. The NOESY spectrum of 2 in DMSO-d6. 
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 Figure S20. HR-ESI mass spectrum of 2. 
  
  
Figure S21. 1H NMR spectrum of 3 in DMSO-d6. 
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Figure S22. 13C NMR spectrum of 3 in DMSO-d6. 
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 Figure S23. HR-ESI mass spectrum of 3. 
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